Evaluation of Woulgan in Diabetic Foot Ulcer

NCT ID: NCT02631512

Last Updated: 2019-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2019-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of the current study is to support the performance and safety of Woulgan® in the treatment of diabetic foot ulcer in comparison with the commercially available hydrogel Intrasite. Healing and untoward medical events to be evaluated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetic Foot Ulcers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Woulgan Gel

Primary dressing with Woulgan Gel with Soluble Beta-Glucan (SBG)

Group Type OTHER

Woulgan Gel

Intervention Type DEVICE

Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.

Intrasite Hydrogel

Primary dressing with Intrasite Hydrogel

Group Type OTHER

Intrasite Hydrogel

Intervention Type DEVICE

Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Woulgan Gel

Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.

Intervention Type DEVICE

Intrasite Hydrogel

Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Type I or II diabetes mellitus.
* Target ulcer area between 0.5 and 5 sqcm, and more than 4 weeks old.
* Ankle-brachial pressure index above 0.7.

Exclusion Criteria

* Ulcers due to non-diabetic etiology.
* Uncontrolled diabetes defined as HbA1c above 70 mmol/mol and insufficient nutritional status.
* Ulcers older than 1 year.
* Any of gangrene, osteomyelitis, cellulitis, or Charcot osteoarthropathy.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Biotec Pharmacon ASA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Magnus Londahl, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Skane University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Skaane University Hospital

Lund, , Sweden

Site Status

North Middlesex University Hospital

London, , United Kingdom

Site Status

Nottingham University Hospital

Nottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

WBG-03

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Treatment of Diabetic Foot Ulcers With AUP1602-C
NCT04281992 COMPLETED PHASE1/PHASE2
Diabetic Foot Ulcer Research Study
NCT05762432 RECRUITING NA